The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001175369
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
1/09/2026
Date registered
Help: Date registered
22/09/2026
Date last updated
Help: Date last updated
22/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
22/09/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Spark: A pilot mixed methods study exploring the experience of using an ankle exoskeleton when incorporated into a block of therapy for people with cerebral palsy
Scientific title
Spark: A pilot mixed methods study exploring the experience of using an ankle exoskeleton when incorporated into a block of therapy for people with cerebral palsy
Additional trial identifiers [1] 318325 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
cerebral palsy 343453 0
Condition category
Condition code
Neurological 339551 339551 0 0
Other neurological disorders
Physical Medicine / Rehabilitation 339704 339704 0 0
Other physical medicine / rehabilitation

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Phase 1:
Participants aged 10-65, receiving physiotherapy services at Cerebral Palsy Alliance (CPA), will be invited to participate in the study. The Biomotum Spark, used in bilateral mode, will be incorporated into their block of therapy sessions as deemed appropriate by their treating physiotherapist and may be delivered by a physiotherapist or exercise physiologist, trained in utilising the device. Activities using the device may include walking indoors or outdoors including over uneven ground, stair climbing, balance training, treadmill training, as deemed relevant to the participant goals.
The intervention is delivered by physiotherapists or exercise physiologists working for CPA, face-to-face via their therapy sites in NSW and ACT. The number of sessions the device will be used is based on participant goals as well as the participants' available National Disability Insurance Scheme (NDIS) funding. Participants will use the device for at least 6 sessions, up to 15 sessions (usual session length 60 minutes, recommended device use for at least 30 minutes per session) or until their goal is achieved. Frequency of intervention is at least weekly. Attendance data will be collected through the asset booking system at CPA. There is no unsupervised use of the Biomotum Spark; the device will be controlled by Physiotherapists or Exercise Physiologists at all times, with no device use outside of scheduled therapy sessions.
Phase 2:
Participants in phase 1, as well as clinicians and CPA staff involved in using and implementing the device in clinical practice, will be asked to complete a one-off survey about their use of the technology. A qualitative phenomenological approach will be used to also conduct focus groups and/or semi-structured interviews (depending on participant preference) with participants and their families, clinicians and other CPA staff involved in the implementation of the technology, to further explore how they felt about the use of the device, and their perceptions on the benefits of it, facilitators and barriers to its use in the clinic setting. Each participant will only complete one survey and one focus group or interview. For the exoskeleton users, Phase 2 activities will be completed as soon as possible after the final intervention session. For all other Phase 2 participants, Phase 2 activities will occur within 6 months of them starting to use implement the device. Surveys are anticipated to take no more than 20 minutes to complete. Interviews and focus groups will be scheduled for one hour.
Intervention code [1] 335219 0
Rehabilitation
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 346732 0
Goal attainment
Timepoint [1] 346732 0
Baseline, post-intervention, 3 months post-intervention, 6 months post-intervention. The 'post-intervention' timepoint will be after the last intervention session (which varies between 6 or up to 15 sessions depending upon participant schedules).
Primary outcome [2] 346873 0
Goal attainment
Timepoint [2] 346873 0
Baseline, post-intervention, 3 months post-intervention, 6 months post-intervention. The 'post-intervention' timepoint will be after the last intervention session (which varies between 6 or up to 15 sessions depending upon participant schedules).
Secondary outcome [1] 467188 0
Gross motor function
Timepoint [1] 467188 0
Baseline, post-intervention. The 'post-intervention' timepoint will be after the last intervention session (which varies between 6 or up to 15 sessions depending upon participant schedules).
Secondary outcome [2] 467189 0
Balance confidence
Timepoint [2] 467189 0
Baseline, post-intervention. The 'post-intervention' timepoint will be after the last intervention session (which varies between 6 or up to 15 sessions depending upon participant schedules).
Secondary outcome [3] 467190 0
Endurance
Timepoint [3] 467190 0
Baseline, post-intervention. The 'post-intervention' timepoint will be after the last intervention session (which varies between 6 or up to 15 sessions depending upon participant schedules).
Secondary outcome [4] 467191 0
Balance and higher level mobility
Timepoint [4] 467191 0
Baseline, post-intervention. The 'post-intervention' timepoint will be after the last intervention session (which varies between 6 or up to 15 sessions depending upon participant schedules).
Secondary outcome [5] 467195 0
Fatigue
Timepoint [5] 467195 0
Every session using the Spark ankle orthosis
Secondary outcome [6] 467196 0
User satisfaction
Timepoint [6] 467196 0
Post-intervention. The 'post-intervention' timepoint will be after the last intervention session (which varies between 6 or up to 15 sessions depending upon participant schedules).
Secondary outcome [7] 467197 0
Pain
Timepoint [7] 467197 0
Every session using the Spark ankle orthosis
Secondary outcome [8] 467198 0
Process of implementation
Timepoint [8] 467198 0
Within 6 months of implementation of the Biomotum Spark at CPA.
Secondary outcome [9] 467199 0
Experience of clinical use
Timepoint [9] 467199 0
As soon as possible post-intervention. The 'post-intervention' timepoint will be after the last intervention session (which varies between 6 or up to 15 sessions depending upon participant schedules).

Eligibility
Key inclusion criteria
Phase 1:
Aged 10-65
Diagnosis of cerebral palsy, classified Gross Motor Function Classification Scale Levels I-IV
Client of Cerebral Palsy Alliance therapy services
Planned block of intervention with Biomotum Spark of at least 6 sessions.

Phase 2:
Participants of phase 1 will be invited to participate in phase 2, along with their parents or significant others in their lives (e.g. in the case of an adult living in a group home, a significant other could be their support worker/group home manager).
Clinicians (physiotherapists or exercise physiologists) and staff involved in the implementation of the ankle exoskeleton at CPA (including client engagement, executive, and clinical education) will also be invited to participate in phase 2.
Minimum age
10 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Phase 1:
Musculoskeletal conditions that would prevent the safe use of ankle assistance or resistance, including:
15 degrees

Orthopaedic surgery on foot, ankle, or leg completed in the prior 6-months
Diagnosis of severe osteoporosis (low bone density; T-score measuring <-2.5)
Cardiovascular disease that prevents mild-moderate physical activity
Unreliable ”yes”/”no” communication (verbal or non-verbal)
Unreliable ability to indicate that they are experiencing pain anywhere in their body
Inability to follow two step instructions

Phase 2:
Nil exclusion criteria

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
Data analysis for this small-scale study will primarily focus on descriptive statistics and visual representation of trends over time. For each outcome measure, we will calculate and report means, standard deviations, and ranges at each timepoint. We will conduct a detailed qualitative analysis of the data, noting any consistent patterns, divergences between participants, or notable changes from baseline. The study will not seek to be powered.

Change scores for each outcome from baseline will be tested using independent t tests for continuous variables and Chi2 tests for categorical variables. Differences from baseline, post intervention will be evaluated for statistical significance. All analyses will be conducted on an intention-to-treat basis, with missing follow-up data conservatively imputed using the last observation carried forward method. All statistical analysis will be conducted by a qualified statistician.

Where a participant may choose to withdraw from the study, but they consent to their information remaining within the study, their data will be managed using the intention to treat method, where the last values obtained for each outcome measure will be carried forward to each subsequent timepoint.

Along with the 25 study participants in phase 1, it is anticipated that phase 2 will include up to 10 clinicians, and up to 30 additional staff involved in the process of implementation.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 30135 0
Cerebral Palsy Alliance - Allambie Heights
Recruitment postcode(s) [1] 46529 0
2100 - Allambie Heights

Funding & Sponsors
Funding source category [1] 322883 0
Charities/Societies/Foundations
Name [1] 322883 0
Cerebral Palsy Alliance
Country [1] 322883 0
Australia
Primary sponsor type
University
Name
University of Sydney
Address
Country
Australia
Secondary sponsor category [1] 325811 0
Charities/Societies/Foundations
Name [1] 325811 0
Cerebral Palsy Alliance
Address [1] 325811 0
Country [1] 325811 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321315 0
The University of Sydney Human Research Ethics Committee
Ethics committee address [1] 321315 0
Ethics committee country [1] 321315 0
Australia
Date submitted for ethics approval [1] 321315 0
23/03/2026
Approval date [1] 321315 0
13/07/2026
Ethics approval number [1] 321315 0
2024/HE001075

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 153334 0
Dr Nicola Postol
Address 153334 0
Cerebral Palsy Alliance Research Institute, Ground floor, Unit 53, 66-70 Parramatta Road (The Edge), Camperdown, NSW, 2050
Country 153334 0
Australia
Phone 153334 0
+61439688582
Fax 153334 0
Email 153334 0
Contact person for public queries
Name 153335 0
Dr Nicola Postol
Address 153335 0
Cerebral Palsy Alliance Research Institute, Ground floor, Unit 53, 66-70 Parramatta Road (The Edge), Camperdown, NSW, 2050
Country 153335 0
Australia
Phone 153335 0
+61439688582
Fax 153335 0
Email 153335 0
Contact person for scientific queries
Name 153336 0
Dr Nicola Postol
Address 153336 0
Cerebral Palsy Alliance Research Institute, Ground floor, Unit 53, 66-70 Parramatta Road (The Edge), Camperdown, NSW, 2050
Country 153336 0
Australia
Phone 153336 0
+61439688582
Fax 153336 0
Email 153336 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
What individual participant data might be shared?
• De-identified individual participant data:
• All outcomes data
• Published results
• Primary outcome(s)
• Safety data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.